C4 Therapeutics, Inc. (CCCC) Free cash flow 2019–2025
C4 Therapeutics, Inc. (CCCC) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$99.3MFY2025 · since FY2019: $54.3M → -$99.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$99.3M | -52.0% |
| FY2024 | -$65.3M | +39.8% |
| FY2023 | -$108.5M | +2.6% |
| FY2022 | -$111.4M | -26.3% |
| FY2021 | -$88.2M | -30.0% |
| FY2020 | -$67.9M | -225.1% |
| FY2019 | $54.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice